RAFFLES MEDICAL GROUP LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.01 SGD | -0.98% |
|
0.00% | -6.48% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,828 | 1,855 | 2,560 | 2,595 | 2,006 | 1,876 | - | - |
| Enterprise Value (EV) 1 | 1,876 | 1,823 | 2,469 | 2,415 | 1,733 | 1,604 | 1,541 | 1,531 |
| P/E ratio | 30.1 x | 27.8 x | 30.5 x | 18.2 x | 22.4 x | 25.8 x | 22.6 x | 21.2 x |
| Yield | 2.5% | 2.51% | 2.04% | 2.71% | 2.22% | 2.28% | 2.66% | 2.18% |
| Capitalization / Revenue | 3.5 x | 3.26 x | 3.54 x | 3.39 x | 2.84 x | 2.64 x | 2.46 x | 2.35 x |
| EV / Revenue | 3.59 x | 3.21 x | 3.41 x | 3.15 x | 2.45 x | 2.26 x | 2.02 x | 1.91 x |
| EV / EBITDA | 17.8 x | 14.7 x | 15.4 x | 10.2 x | 11.3 x | 11.8 x | 10.2 x | 9.76 x |
| EV / FCF | 131 x | 25.7 x | 22.4 x | 13.9 x | 10.3 x | -318 x | 15.1 x | 14 x |
| FCF Yield | 0.76% | 3.89% | 4.46% | 7.18% | 9.74% | -0.31% | 6.63% | 7.12% |
| Price to Book | 2.17 x | 2.06 x | 2.68 x | 2.56 x | 1.95 x | 1.79 x | 1.73 x | 1.65 x |
| Nbr of stocks (in thousands) | 1,827,859 | 1,864,327 | 1,868,290 | 1,853,918 | 1,857,011 | 1,857,071 | - | - |
| Reference price 2 | 1.000 | 0.9950 | 1.370 | 1.400 | 1.080 | 1.010 | 1.010 | 1.010 |
| Announcement Date | 2/23/20 | 2/21/21 | 2/20/22 | 2/26/23 | 2/26/24 | - | - | - |
1SGD in Million2SGD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 522 | 568.2 | 723.8 | 766.5 | 706.9 | 709.7 | 762 | 799.4 |
| EBITDA 1 | 105.4 | 123.9 | 160.6 | 236.1 | 154 | 135.5 | 151.1 | 156.8 |
| EBIT 1 | 76.17 | 88.44 | 121.3 | 195.8 | 115.8 | 95.6 | 109.7 | 115.3 |
| Operating Margin | 14.59% | 15.57% | 16.76% | 25.55% | 16.37% | 13.47% | 14.4% | 14.42% |
| Earnings before Tax (EBT) 1 | 75.92 | 84.44 | 115.6 | 191.7 | 119.4 | 99.41 | 112.8 | 119.7 |
| Net income 1 | 60.27 | 65.89 | 84.17 | 143.5 | 90.15 | 74.59 | 83.96 | 89.42 |
| Net margin | 11.55% | 11.6% | 11.63% | 18.72% | 12.75% | 10.51% | 11.02% | 11.19% |
| EPS 2 | 0.0332 | 0.0358 | 0.0449 | 0.0769 | 0.0482 | 0.0391 | 0.0446 | 0.0476 |
| Free Cash Flow 1 | 14.28 | 70.96 | 110.2 | 173.4 | 168.8 | -5.05 | 102.2 | 109 |
| FCF margin | 2.73% | 12.49% | 15.22% | 22.62% | 23.88% | -0.71% | 13.41% | 13.64% |
| FCF Conversion (EBITDA) | 13.54% | 57.25% | 68.59% | 73.44% | 109.6% | - | 67.63% | 69.55% |
| FCF Conversion (Net income) | 23.69% | 107.69% | 130.89% | 120.82% | 187.23% | - | 121.72% | 121.95% |
| Dividend per Share 2 | 0.0250 | 0.0250 | 0.0280 | 0.0380 | 0.0240 | 0.0230 | 0.0269 | 0.0220 |
| Announcement Date | 2/23/20 | 2/21/21 | 2/20/22 | 2/26/23 | 2/26/24 | - | - | - |
1SGD in Million2SGD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2023 S1 |
|---|---|---|---|
| Net sales 1 | 190 | 190 | 370.8 |
| EBITDA | - | - | - |
| EBIT 1 | 34.3 | 34.3 | - |
| Operating Margin | 18.05% | 18.05% | - |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 2/26/23 | 2/20/22 | 7/30/23 |
1SGD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 48.6 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 32.1 | 90.8 | 180 | 273 | 272 | 334 | 345 |
| Leverage (Debt/EBITDA) | 0.4605 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 14.3 | 71 | 110 | 173 | 169 | -5.05 | 102 | 109 |
| ROE (net income / shareholders' equity) | 7.34% | 7.57% | 9.05% | 14.5% | 8.84% | 7.13% | 7.7% | 7.9% |
| ROA (Net income/ Total Assets) | 5.02% | 4.9% | 5.71% | 9.43% | 5.89% | 4.65% | 4.87% | 5.18% |
| Assets 1 | 1,201 | 1,344 | 1,475 | 1,521 | 1,530 | 1,604 | 1,725 | 1,728 |
| Book Value Per Share 2 | 0.4600 | 0.4800 | 0.5100 | 0.5500 | 0.5500 | 0.5600 | 0.5800 | 0.6100 |
| Cash Flow per Share 2 | 0.0600 | 0.0700 | 0.0900 | 0.1100 | 0.1000 | 0.0200 | 0.0700 | 0.0700 |
| Capex 1 | 96.1 | 58.9 | 49.9 | 25 | 20.5 | 24.1 | 28.2 | 27.5 |
| Capex / Sales | 18.41% | 10.36% | 6.9% | 3.26% | 2.9% | 3.39% | 3.7% | 3.44% |
| Announcement Date | 2/23/20 | 2/21/21 | 2/20/22 | 2/26/23 | 2/26/24 | - | - | - |
1SGD in Million2SGD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
1.01
SGD
Average target price
1.135
SGD
Spread / Average Target
+12.38%
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- BSL Stock
- Financials Raffles Medical Group Ltd
